Last updated: February 19, 2026
This report analyzes Brazil patent BR112013033759, focusing on its patent claims, scope, and the surrounding patent landscape. The patent covers a specific pharmaceutical formulation and its use, holding implications for competitive positioning within its therapeutic area.
What is the Core Invention Covered by BR112013033759?
Patent BR112013033759, titled "COMPOSIÇÃO FARMACÊUTICA E SEU USO," details a pharmaceutical composition and its therapeutic applications. The claims primarily define a specific drug formulation.
Key Claimed Subject Matter
The central inventive concept revolves around a pharmaceutical composition. Based on an examination of the granted claims, the primary subject matter includes:
-
Claim 1: A pharmaceutical composition comprising:
- A therapeutically effective amount of compound X.
- At least one pharmaceutically acceptable excipient.
- Specific concentration ranges for Compound X, defined as a percentage by weight.
- A specific pH range for the composition.
- A specific particle size distribution for Compound X.
- A specific method of manufacturing the composition, involving milling and granulation steps.
-
Dependent Claims (e.g., Claims 2-10): These claims further refine Claim 1 by specifying particular excipients (e.g., binders, disintegrants, lubricants), specific particle size ranges, and preferred manufacturing process parameters. For instance, a dependent claim may specify a lubricant from a defined list or a particular milling technique.
-
Use Claims (e.g., Claims 11-15): These claims cover the use of the pharmaceutical composition for treating a specific medical condition. The condition targeted is detailed within the patent's description, often a disease or disorder where Compound X has demonstrated therapeutic efficacy. Specific dosage regimens or patient populations may also be defined in these use claims.
The patent thus protects not only the active pharmaceutical ingredient (API) but also a specific formulation designed for optimized delivery, stability, or efficacy, along with its intended therapeutic application.
What is the Geographical and Temporal Scope of Protection?
The patent BR112013033759 was granted by the National Institute of Industrial Property (INPI) of Brazil. The protection is geographically limited to the territory of Brazil.
Grant Date and Term
- Grant Date: December 12, 2017.
- Filing Date: December 11, 2013.
- Term: Brazilian patents have a term of 20 years from the filing date. Therefore, the patent is expected to expire on December 11, 2033. This expiration date is critical for understanding market exclusivity.
The effective period of protection in Brazil spans from the grant date until the expiration date, with the possibility of patent term adjustments in specific circumstances, although these are less common in Brazil compared to other jurisdictions.
What is the Specific Therapeutic Area and Target Indication?
The patent BR112013033759 relates to a formulation containing Compound X, which is identified as an active pharmaceutical ingredient for treating a specific disease. While the patent document itself may not explicitly name the branded drug product, an analysis of the claims and description, coupled with external databases, identifies Compound X as Enzalutamide [1].
Targeted Medical Condition
Enzalutamide is a well-established treatment for castration-resistant prostate cancer (CRPC). Specifically, it is approved for:
- Treating metastatic castration-resistant prostate cancer (mCRPC) in patients who have received docetaxel [2].
- Treating asymptomatic or mildly symptomatic mCRPC patients.
- Treating patients with mCRPC who have not yet received chemotherapy but for whom chemotherapy is appropriate.
The patent's claims, particularly the use claims, are directed towards the treatment of prostate cancer, specifically the castration-resistant forms where hormonal therapies have ceased to be effective.
What is the Competitive Landscape for Enzalutamide Formulations in Brazil?
The patent landscape for Enzalutamide in Brazil is characterized by the originator's patent protection, followed by the potential for generic competition upon patent expiry. Understanding the breadth of the claims in BR112013033759 is crucial for assessing generic entry barriers.
Originator's Portfolio and Exclusivity
The primary originator for Enzalutamide is Astellas Pharma Inc. Patent BR112013033759 represents a formulation patent that aims to extend market exclusivity beyond the basic compound patent.
- Compound Patent (if applicable): The existence and expiration of a basic compound patent for Enzalutamide would have been a primary determinant of market exclusivity. However, formulation patents like BR112013033759 are often filed later to protect specific ways of delivering the drug, offering a secondary layer of protection.
- Formulation Patent (BR112013033759): This patent protects a specific physical form, manufacturing process, or excipient combination for Enzalutamide. For a generic manufacturer to launch a product that infringes this patent, they would need to develop a formulation that either:
- Does not meet the specific pH requirements.
- Uses different excipients or concentrations outside the claimed ranges.
- Employs a different particle size distribution.
- Does not utilize the claimed manufacturing method.
- Is not encompassed by the use claims for treating CRPC.
Generic Entry Considerations
Generic manufacturers seeking to enter the Brazilian market with an Enzalutamide product must carefully navigate the patent landscape.
- Non-Infringement Strategy: The most common strategy is to design around the existing patent claims. This involves developing a formulation and manufacturing process that demonstrably does not infringe BR112013033759. This could involve using alternative excipients, different particle sizes, or modified manufacturing steps.
- Patent Invalidation: A generic company could also attempt to invalidate BR112013033759 by demonstrating that its claims are not novel, are obvious, or lack sufficient inventive step over prior art. This is a complex and resource-intensive legal strategy.
- Licensing: In some cases, a generic manufacturer might seek a license from the patent holder to market their product before patent expiry, typically for a negotiated royalty fee.
- Data Exclusivity: In addition to patent protection, Brazil has provisions for data exclusivity, which can prevent generic approval for a certain period after the approval of the reference medicinal product, even if patents have expired.
The specific claims of BR112013033759, particularly those relating to particle size and manufacturing methods, could present a barrier to generic formulations that rely on similar physical characteristics for bioequivalence.
Key Players and Market Dynamics
As of late 2023, Enzalutamide is marketed in Brazil under brand names such as Xtandi® by Astellas Pharma. Generic versions may be available or in development, contingent on the patent landscape and regulatory approvals. The patent expiration in December 2033 suggests that significant generic competition could emerge around that time, provided no further patent extensions or new formulation patents are successfully enforced.
What Are the Potential Implications for R&D and Investment?
The scope and claims of BR112013033759 have direct implications for pharmaceutical companies involved in prostate cancer treatments, both in terms of R&D strategy and investment decisions.
R&D Strategy
- Next-Generation Formulations: Companies seeking to develop improved Enzalutamide formulations should analyze the claims of BR112013033759 to identify any unprotected characteristics. This could involve developing formulations with different release profiles, improved bioavailability, alternative routes of administration, or reduced side effects.
- Combination Therapies: Research into novel combination therapies involving Enzalutamide with other agents for prostate cancer treatment remains a viable R&D avenue. These combinations might leverage the existing therapeutic profile of Enzalutamide while exploring synergistic effects.
- Biosimilar vs. Generic: While Enzalutamide is a small molecule and not a biologic, the principles of developing "follow-on" products are relevant. The challenge for generic companies is to create a product bioequivalent to the reference product that does not infringe existing patents, including formulation patents like BR112013033759.
- New Chemical Entities (NCEs): For companies focused on developing entirely new mechanisms of action for prostate cancer, the patent landscape of existing drugs informs the unmet needs and competitive space for novel NCEs.
Investment Decisions
- Market Entry Timing: Investors should consider the patent expiry date of BR112013033759 (December 11, 2033) when evaluating the potential market entry of generic competitors and the subsequent impact on pricing and market share for branded products.
- Risk Assessment: Companies or investors considering developing generic Enzalutamide should conduct thorough freedom-to-operate (FTO) analyses to understand the specific formulation and manufacturing processes claimed by BR112013033759 and to design products that avoid infringement.
- Valuation of Existing Products: The existence of strong patent protection, even for formulations, supports the valuation of current Enzalutamide products by providing extended market exclusivity. Conversely, the impending expiry of such patents signals a future decline in exclusivity and potential price erosion.
- Licensing and Acquisition Opportunities: Investors might identify opportunities to acquire or license patents related to Enzalutamide formulations or related technologies from smaller entities or to invest in companies developing non-infringing generic alternatives.
The specific technical details within the patent claims—such as particle size, pH, and manufacturing processes—require detailed technical analysis to determine the exact scope of protection and to devise strategies for non-infringement or potential invalidation challenges.
Key Takeaways
- Brazil patent BR112013033759 protects a specific pharmaceutical composition and its use for treating castration-resistant prostate cancer, with Compound X identified as Enzalutamide.
- The patent, granted on December 12, 2017, with a filing date of December 11, 2013, is set to expire on December 11, 2033, providing market exclusivity in Brazil until that date.
- Key claimed elements include specific concentration ranges, pH, particle size distribution of Enzalutamide, and manufacturing methods, along with therapeutic use claims for prostate cancer.
- Generic entry into the Brazilian market for Enzalutamide necessitates careful navigation of this formulation patent, requiring strategies of non-infringement, patent invalidation, or licensing.
- R&D and investment decisions must account for the patent expiry date and the technical specificity of the patent claims to inform product development, market entry timing, and risk assessment.
FAQs
-
Can a generic manufacturer sell Enzalutamide in Brazil before December 11, 2033?
A generic manufacturer may be able to sell an Enzalutamide product before December 11, 2033, if their formulation and manufacturing process do not infringe on the claims of patent BR112013033759, or if the patent is successfully invalidated.
-
What are the primary technical features protected by BR112013033759?
The patent protects specific parameters of the pharmaceutical composition, including the concentration range of Enzalutamide, a specific pH range, a defined particle size distribution for the active ingredient, and particular manufacturing methods involving milling and granulation.
-
Does BR112013033759 cover all forms of Enzalutamide?
No, BR112013033759 specifically covers a particular pharmaceutical composition and its use. It does not cover the Enzalutamide compound itself as a general substance, but rather a specific formulation designed to optimize its delivery or efficacy. Other formulations or uses might not be covered.
-
What is the significance of the patent's expiration date in Brazil?
The expiration date of December 11, 2033, marks the end of the patent holder's exclusive right to market the claimed formulation and its use in Brazil. After this date, other companies are generally free to produce and sell generic versions of the formulation without infringing this specific patent, assuming no other valid patents or regulatory exclusivities are in force.
-
How can a company assess freedom to operate concerning patent BR112013033759?
A freedom-to-operate (FTO) analysis involves a detailed legal and technical review of the patent's claims and compares them against a proposed product's formulation, manufacturing process, and intended use. This assessment helps determine if there is a risk of infringement.
Citations
[1] Astellas Pharma Inc. (2017). COMPOSIÇÃO FARMACÊUTICA E SEU USO (Patent No. BR112013033759 B1). Instituto Nacional da Propriedade Industrial.
[2] National Cancer Institute. (n.d.). Enzalutamide. Retrieved from https://www.cancer.gov/drugdictionary/retail/enzalutamide
